Crispr Therapeutics shares tumble after significant earnings miss
LONDON - Edinburgh Worldwide Investment Trust plc (LSE:EWI) reported a 2.9% decline in net asset value per share for the six months ending April 30, 2025, outperforming its comparative index which fell 7.2% during the same period, according to an interim financial report released Monday.
The trust’s share price declined by 1.9% during the reporting period, which saw heightened market volatility following what the company described as President Trump’s "Liberation Day" announcement of U.S. tariffs and subsequent retaliatory measures from China in April 2025.
Axon Enterprises, SpaceX and PsiQuantum emerged as the largest positive contributors to performance, while AeroVironment (NASDAQ:AVAV), Sweetgreen and Exact Sciences (NASDAQ:EXAS) were the most significant detractors during the period.
The investment trust, which focuses on long-term capital growth through global equity investments, reported total assets of £660.0 million as of April 30, with loans of £54.4 million. The company’s allocation to private companies increased to 31.1% of total assets, up from 25.3% on October 31, 2024.
During the six-month period, Edinburgh Worldwide bought back 6.3 million shares into treasury.
Jonathan Simpson-Dent, Chair of Edinburgh Worldwide Investment Trust, noted that the reporting period covers "the early stages of implementation of the Company’s reset for growth action plan" which was communicated in November 2024.
The report is based on the unaudited interim financial results approved by the board on June 24, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.